Abstract
Dosage requirements and the therapeutic response vary widely between patients treated with neuroleptic drugs. There are large interindividual differences in the elimination kinetics and in the steady state plasma levels achieved during treatment with a fixed dose of a neuroleptic (Dahl 1986). Thus, pharmacokinetic factors contribute to the variability in drug response. One of the major aims in optimizing neuroleptic treatment has been to search for concentration-effect rather than dose-effect relationships as discussed by Baldessarini et al. (1988). Knowledge of the factors contributing to the pharmacokinetic variability is thus of importance for individualization of drug therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aaes-Jørgensen T, Gravem A, Jørgensen A (1981) Serum levels of the isomers of clopenthixol in patients given cis (Z)-clopenthixol or cis(Z)/trans(E)-clopenthixol. Acta Psychiatr Scand 64 Suppl 294: 70–77
Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91
Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine - a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7: 478–480
Bolvig Hansen L, Larsen NE (1977) Plasma concentrations of perhenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology (Berl) 53: 127–130
Bolvig Hansen L, Larsen NE, Vestergård P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology (Berl) 74: 306–309
Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Chn Pharmacol 36: 537–547
Chakraborty BS, Hubbard JW, Hawes EM, McKay G, Cooper JK, Gurnsey T, Korchinski ED, Midha KK (1989) Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Chn Pharmacol 37: 45–48
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clinn Pharmacokinet 11: 36–61
Dahl M-L, Ekqvist B, Widen J, Bertilsson L (1991) Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 84: 99–102
Dahl-Puustinen M-L, Lidén A, Aim C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 46: 78–81
Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Froemming JS, Francis Lam YW, Jann MW, Davis CM (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet 17: 396–423
Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertilsson L (1992a) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92–97
Llerena A, Dahl M-L, Ekqvist B, Bertilsson L (1992b) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14: 261–264
Otton SV, Inaba T, Kalow W (1983) Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 32: 795–800
Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435
Syvälahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Chn Pharmacol 22: 89–92
Tyndale RF, Kalow W, Inaba T (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Chn Pharmacol 31: 655–660
Von Bahr C, Spina E, Birgersson C, Ericsson Ö, Göransson M, Henthora T, Sjöqvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34: 2501–2505
Von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49: 234–240
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bertilsson, L., Dahl, M.L., Ekqvist, B., Llerena, A. (1993). Disposition of the Neuroleptics Perphenazine, Zuclopenthixol, and Haloperidol Cosegregates with Polymorphic Debrisoquine Hydroxylation. In: Gram, L.F., Balant, L.P., Meltzer, H.Y., Dahl, S.G. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 10. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78010-3_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-78010-3_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78012-7
Online ISBN: 978-3-642-78010-3
eBook Packages: Springer Book Archive